Delving into the Latest Updates on Shanxi Kangbao Biological Product Co. Ltd. with Synapse

Overview

Tags

Other Diseases

Hemic and Lymphatic Diseases

Urogenital Diseases

Small molecule drug

Non-recombinant coagulation factor

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Non-recombinant coagulation factor	3
Small molecule drug	3
Interferons	1
Fusion protein	1
Prophylactic vaccine	1

Top 5 Target	Count

gp41(Transmembrane glycoprotein gp41)	2
IFNAR(Interferon alpha/beta receptor)	1
factor IX(Coagulation factor IX)	1
F8(Coagulation factor VIII)	1
Fibrinogen	1

主要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的安全性和耐受性。次要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药效（PD）作用。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药代动力学（PK）特征。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的免疫原性。探索性目的：探索在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的病毒学治疗失败的情况。

[Translation]

Primary objective: To evaluate the safety and tolerability of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Secondary objectives: To evaluate the pharmacodynamic (PD) effect of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the pharmacokinetic (PK) characteristics of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the immunogenicity of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Exploratory objectives: To explore the failure of virological treatment after multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral treatment.

Start Date28 Aug 2024

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

CTR20233018 / RecruitingPhase 2

评价注射用利普韦肽联合核苷药物在未接受过抗病毒治疗的HIV 感染者中的有效性、安全性的随机、对照、开放、剂量探索临床研究

[Translation] A randomized, controlled, open, dose-finding clinical study to evaluate the efficacy and safety of lepviride for injection combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment

评价注射用利普韦肽联合核苷药物在未接受过抗病毒治疗的HIV 感染者中的有效性、安全性的随机、对照、开放、剂量探索临床研究

[Translation]

A randomized, controlled, open, dose-finding clinical study to evaluate the efficacy and safety of lepviride for injection combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment

Start Date02 Nov 2023

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

100 Clinical Results associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

28

Literatures (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Huagong Sheji Tongxun

Determination of tributyl phosphate in human Coagulation Factor VIII by pre-column derivation

Author: Wu, Peng-hui ; Gao, Hong-qin

Objective To establish a new method for the determining the contents of tri-Bu phosphate in the human coagulation factor VIII.Methods The content of tri-Bu phosphate was determined by gas chromatog.Results Under the selected experiment conditions, there was a good linear relationship for the content of tri-Bu phosphate in the range of 2-16μg/L.The RSD was 0.11% in the accuracy test.The RSD was 9.6% in the repeatability test.The average recovery rate was 91% with RSD 5.1%.Conclusion The method is accurate to determine the contents of tri-Bu phosphate in the human Coagulation Factor VIII, and can be used to determine the contents of tri-Bu phosphate in the human Coagulation Factor VIII.

Zhongguo Shengwu Zhipinxue Zazhi

Expression of recombinant human VEGF/rGEL fusion toxin in E. coli and purification and activity of expressed product

Author: Sun, Hong-yan ; Wu, Fu-jun ; Shen, Yun-fei ; Li, Yue ; Liu, Ai-jun ; Zhou, Man-xiang ; Shen, Yan-jie ; Liu, Min-xia

Objective: To express recombinant human vascular endothelial growth factor (VEGF)_121KDR/rGEL fusion toxin, specific to VEGF receptor 2 (VEGFR2) KDR, in E. coli, purify the expressed product and determine its biol. activity.Methods: The gene sequence of VEGF_121KDR/rGEL fusion toxin were cloned into prokaryotic expression vector pET-32a(+), and the constructed recombinant plasmid pET-32a(+)-VEGF_121KDR/rGEL was transformed to E. coli Origami (DE3) for expression under induction of IPTG.The expressed protein was purified by SP-Sepharose FF and NiSepharose FF chromatog., then digested with thrombin, further purified by Q-Sepharose FF chromatog., and determined for cytotoxicity to PAE/FLT1 and PAE/KDR cells on which VEGFR1/FLT1 and VEGFR2/KDR were highly expressed.Results: Restriction anal. and sequencing proved that recombinant plasmid pET-32a(+)-VEGF_121KDR/rGEL was constructed correctly.The fusion protein of thioredoxin (Trx) as a tag and rhVEGF_121KDR/rGEL, with a relative mol. mass of about 62 000, was expressed in a soluble form, and contained about 20% of total somatic protein.However, the relative mol. mass of purified rhVEGF_121KDR/rGEL fusion toxin, after removal of tag, was about43 000, while the purity was more than 98%.The median inhibitory concentrations (IC₅₀) of VEGFR1-pos. PAE/FLT cells was 278 nmol/L, which was more than 800 times of that of VEGFR2-pos. PAE/KDR cells (0.32 nmol/L).Conclusion: The rhVEGF_121KDR/rGEL fusion toxin was successfully expressed in E. coli, which showed strong killing effect on vascular endothelial cells overexpressing VEGFR2.It laid a foundation of further study on the anti-tumor effect of the fusion toxin and development of novel drugs targeting tumors.

Shanxi Yike Daxue Xuebao

Determination of glycine in human coagulation factor VIII by pre-column derivation

Author: Cui, Su-mei ; Gao, Hong-qin

A new method for determining the contents of glycine in the human coagulation factor VIII was established.The content of glycine was determined using internal standard method by HPLC on the reversed phase chromatog. column at the wavelength of 254 nm.The resolution of glycine and internal standard substance was consistent with the requirements.There was a good linear relationship for glycine in the range of 0.135 2-0.811 2 mg/mL.The RSD was 0.13% in the accuracy test.The average recovery rate was 99.73% with RSD of 1.03%.RSD of the stability was 1.2% for sample solutionsThe established method is accurate, and can be used to determine the contents of glycine in the human coagulation factor VIII.

100 Deals associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

3

Phase 1 Clinical

Phase 2 Clinical

2

3

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Human Prothrombin Complex Concentrate(Shanxi Kangbao Biological Products) ( factor IX )	Hemophilia B More	Approved
Factor VIII(Shanxi Kangbao Biological Products) ( F8 )	Hemophilia A More	Approved
Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.) ( Fibrinogen )	Afibrinogenemia More	Approved
LP-98 ( gp41 )	HIV Infections More	Phase 2
Lipovirtide ( gp41 )	HIV Infections More	Phase 2